PrEP Users With AUD Under-Treated, Study Finds
June 2, 2025
-
3 min
6 Key Takeaways
-
1
15% of patients initiating PrEP had an alcohol use disorder diagnosis within 6 months.
-
2
Only
-
3
46% of patients with AUD received an FDA-approved medication.
-
4
The underdiagnosis of AUD prior to PrEP initiation and undertreatment following initiation was highlighted.
-
5
The study emphasized integrating mental health assessments into regular care alongside PrEP services.
-
6
Improved screening and access to evidence-based treatments for AUD in this population is necessary to support PrEP adherence and HIV prevention efforts.
A recent study found that nearly 15% of patients initiating human immunodeficiency virus preexposure prophylaxis (PrEP) had an alcohol use disorder (AUD) diagnosis within 6 months, with only a small proportion receiving FDA-approved treatment. The study also highlighted the underdiagnosis of AUD prior to PrEP initiation and undertreatment following initiation, emphasizing the need for improved screening and access to evidence-based treatments for AUD in this population.
Listen Tab content